Tumor adaptation and resistance to RAF inhibitors

Nature Medicine

Volumn 19, Issue 11, 2013, Pages 1401-1409

  Lito, Piro ^a   Rosen, Neal ^a   Solit, David B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; DABRAFENIB; DACARBAZINE; DUAL SPECIFICITY PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROFIBROMIN; SPROUTY PROTEIN; TRAMETINIB; VEMURAFENIB;

ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; COMPETITIVE INHIBITION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DIMERIZATION; DRUG EFFICACY; FUNCTIONAL GENOMICS; HAIRY CELL LEUKEMIA; HALF LIFE TIME; HUMAN; KERATOACANTHOMA; MELANOMA; MELANOMA CELL; MONOTHERAPY; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RASH; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STEADY STATE; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; TUMOR REGRESSION; WILD TYPE;

ADAPTATION, PHYSIOLOGICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RAF KINASES;

EID: 84887478023     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3392     Document Type: Review

References (111)

1. Kolch, W., Heidecker, G., Lloyd, P. & Rapp, U.R. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349, 426-428 (1991).
2. Kyriakis, J.M. et al. Raf-1 activates MAP kinase-kinase. Nature 358, 417-421 (1992).
3. Rapp, U.R. et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc. Natl. Acad. Sci. USA 80, 4218-4222 (1983).
4. Moelling, K., Heimann, B., Beimling, P., Rapp, U.R. & Sander, T. Serine-and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins. Nature 312, 558-561 (1984).
5. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
6. Nimnual, A. & Bar-Sagi, D. The two hats of SOS. Sci. STKE 2002, pe36 (2002).
7. Boguski, M.S. & McCormick, F. Proteins regulating Ras and its relatives. Nature 366, 643-654 (1993).
8. Cutler, R.E. Jr., Stephens, R.M., Saracino, M.R. & Morrison, D.K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl. Acad. Sci. USA 95, 9214-9219 (1998).
9. Chong, H. & Guan, K.L. Regulation of Raf through phosphorylation and N terminus-C terminus interaction. J. Biol. Chem. 278, 36269-36276 (2003).
10. Dhillon, A.S. et al. Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol. Cell. Biol. 22, 3237-3246 (2002).
11. Clark, G.J. et al. 14-3-3 z negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain. J. Biol. Chem. 272, 20990-20993 (1997).
12. Light, Y., Paterson, H. & Marais, R. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol. Cell. Biol. 22, 4984-4996 (2002).
13. Ory, S., Zhou, M., Conrads, T.P., Veenstra, T.D. & Morrison, D.K. Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr. Biol. 13, 1356-1364 (2003).
14. Abraham, D. et al. Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J. Biol. Chem. 275, 22300-22304 (2000).
15. Zhang, X.F. et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364, 308-313 (1993).
16. Warne, P.H., Viciana, P.R. & Downward, J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364, 352-355 (1993).
17. Vojtek, A.B., Hollenberg, S.M. & Cooper, J.A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205-214 (1993).
18. Moodie, S.A., Willumsen, B.M., Weber, M.J. & Wolfman, A. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260, 1658-1661 (1993).
19. Williams, J.G. et al. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J. Biol. Chem. 275, 22172-22179 (2000).
20. Bondeva, T., Balla, A., Varnai, P. & Balla, T. Structural determinants of Ras-Raf interaction analyzed in live cells. Mol. Biol. Cell 13, 2323-2333 (2002).
21. Mott, H.R. et al. The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. Proc. Natl. Acad. Sci. USA 93, 8312-8317 (1996).
22. Marais, R., Light, Y., Paterson, H.F., Mason, C.S. & Marshall, C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 272, 4378-4383 (1997).
23. Mason, C.S. et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18, 2137-2148 (1999).
24. Fabian, J.R., Daar, I.O. & Morrison, D.K. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell. Biol. 13, 7170-7179 (1993).
25. Tran, N.H., Wu, X. & Frost, J.A. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. J. Biol. Chem. 280, 16244-16253 (2005).
26. Udell, C.M., Rajakulendran, T., Sicheri, F. & Therrien, M. Mechanistic principles of RAF kinase signaling. Cell. Mol. Life Sci. 68, 553-565 (2011).
27. Zhang, B.H. & Guan, K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429-5439 (2000).
28. Farrar, M.A., Alberol-Ila, J. & Perlmutter, R.M. Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization. Nature 383, 178-181 (1996).
29. Luo, Z. et al. Oligomerization activates c-Raf-1 through a Ras-dependent mechanism. Nature 383, 181-185 (1996).
30. Rushworth, L.K., Hindley, A.D., O'Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 26, 2262-2272 (2006).
31. Wan, P.T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
32. Grbovic, O.M. et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA 103, 57-62 (2006).
33. Tzivion, G. & Avruch, J. 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation. J. Biol. Chem. 277, 3061-3064 (2002).
34. Brennan, D.F. et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472, 366-369 (2011).
35. Clapéron, A. & Therrien, M. KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 26, 3143-3158 (2007).
36. Matallanas, D. et al. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2, 232-260 (2011).
37. Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875-885 (2004).
38. Roskoski, R. Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol. Res. 66, 105-143 (2012).
39. Avraham, R. & Yarden, Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12, 104-117 (2011).
40. Li, X., Huang, Y., Jiang, J. & Frank, S.J. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell. Signal. 20, 2145-2155 (2008).
41. Corbalan-Garcia, S., Yang, S.S., Degenhardt, K.R. & Bar-Sagi, D. Identification of the mitogen-activated protein kinase phosphorylation sites on human Sos1 that regulate interaction with Grb2. Mol. Cell. Biol. 16, 5674-5682 (1996).
42. Douville, E. & Downward, J. EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2. Oncogene 15, 373-383 (1997).
43. von Kriegsheim, A. et al. Cell fate decisions are specified by the dynamic ERK interactome. Nat. Cell Biol. 11, 1458-1464 (2009).
44. Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593-604 (2001).
45. Dougherty, M.K. et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 17, 215-224 (2005).
46. Häfner, S. et al. Mechanism of inhibition of Raf-1 by protein kinase A. Mol. Cell. Biol. 14, 6696-6703 (1994).
47. Balan, V. et al. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol. Biol. Cell 17, 1141-1153 (2006).
48. Pagès, G., Brunet, A., L'Allemain, G. & Pouyssegur, J. Constitutive mutant and putative regulatory serine phosphorylation site of mammalian MAP kinase kinase (MEK1). EMBO J. 13, 3003-3010 (1994).
49. Pratilas, C.A. et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 106, 4519-4524 (2009).
50. Joseph, E.W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 107, 14903-14908 (2010).
51. Amit, I. et al. A module of negative feedback regulators defines growth factor signaling. Nat. Genet. 39, 503-512 (2007).
52. Brondello, J.M., Brunet, A., Pouyssegur, J. & McKenzie, F.R. The dual specificity mitogen-activated protein kinase phosphatase-1 and-2 are induced by the p42/p44MAPK cascade. J. Biol. Chem. 272, 1368-1376 (1997).
53. Kim, H.J. & Bar-Sagi, D. Modulation of signalling by Sprouty: a developing story. Nat. Rev. Mol. Cell Biol. 5, 441-450 (2004).
54. Hanafusa, H., Torii, S., Yasunaga, T. & Nishida, E. Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway. Nat. Cell Biol. 4, 850-858 (2002).
55. Mason, J.M. et al. Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. Mol. Biol. Cell 15, 2176-2188 (2004).
56. Sasaki, A. et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Cell Cycle 2, 281-282 (2003).
57. Stowe, I.B. et al. A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev. 26, 1421-1426 (2012).
58. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
59. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
60. Andreadi, C. et al. The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. Genes Dev. 26, 1945-1958 (2012).
61. Poulikakos, P.I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
62. Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668-682 (2012).
63. Tsavachidou, D. et al. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Cancer Res. 64, 5556-5559 (2004).
64. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
65. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
66. Hauschild, A. et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012).
67. Flaherty, K.T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114 (2012).
68. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
69. Xing, F. et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31, 446-457 (2012).
70. Sosman, J.A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
71. Solit, D.B. & Rosen, N. Resistance to BRAF inhibition in melanomas. N. Engl. J. Med. 364, 772-774 (2011).
72. Heidorn, S.J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
73. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
74. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
75. Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
76. Oberholzer, P.A. et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J. Clin. Oncol. 30, 316-321 (2012).
77. Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207-215 (2012).
78. Lacouture, M.E., O'Reilly, K., Rosen, N. & Solit, D.B. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J. Clin. Oncol. 30, 329-330 (2012).
79. Callahan, M.K. et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N. Engl. J. Med. 367, 2316-2321 (2012).
80. Kopetz, S. et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J. Clin. Oncol. 28 (suppl.), abstr. 3534 (2010).
81. Planchard, D. et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients. J. Clin. Oncol. 31 (suppl.), abstr. 8009 (2013).
82. Yang, H. et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 72, 779-789 (2012).
83. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
84. Maertens, O. et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3, 338-349 (2013).
85. Whittaker, S.R. et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350-362 (2013).
86. Whittaker, S. et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci. Transl. Med. 2, 35ra41 (2010).
87. Weisbart, R.H. et al. BRAF splice variants in rheumatoid arthritis synovial fibroblasts activate MAPK through CRAF. Mol. Immunol. 55, 247-252 (2013).
88. Shi, H. et al. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
89. Montagut, C. et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 68, 4853-4861 (2008).
90. Johannessen, C.M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
91. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
92. Antony, R., Emery, C.M., Sawyer, A.M. & Garraway, L.A. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 73, 4840-4851 (2013).
93. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
94. Shi, H. et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2, 414-424 (2012).
95. Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
96. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695 (2010).
97. Wilson, T.R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
98. Girotti, M.R. et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov. 3, 158-167 (2013).
99. Montero-Conde, C. et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Discov. 3, 520-533 (2013).
100. O'Reilly, K.E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
101. Carver, B.S. et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19, 575-586 (2011).
102. Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 (2011).
103. Corcoran, R.B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227-235 (2012).
104. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
105. Flaherty, K.T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012).
106. Falchook, G.S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782-789 (2012).
107. Morris, E.J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750 (2013).
108. Smalley, K.S. et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol. Cancer Ther. 7, 2876-2883 (2008).
109. Freeman, A.K., Ritt, D.A. & Morrison, D.K. Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol. Cell 49, 751-758 (2013).
110. Sievert, A.J. et al. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc. Natl. Acad. Sci. USA 110, 5957-5962 (2013).
111. Das Thakur M.,et al.,Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.Nature 494 251-255 (2013).